Please login to the form below

Not currently logged in
Email:
Password:

BMS-986094

This page shows the latest BMS-986094 news and features for those working in and with pharma, biotech and healthcare.

Merck agrees $3.85bn deal for hepatitis specialist Idenix

Merck agrees $3.85bn deal for hepatitis specialist Idenix

Bristol-Myers Squibb's BMS-986094 that was discontinued in 2012. ... Merck and other rivals, including Johnson &Johnson and AbbVie, as well as BMS and Gilead, are vying to develop regimens that reduce the duration of therapy down below 12 weeks and

Latest news

  • AbbVie gets 'breakthrough' status for hepatitis C regimen AbbVie gets 'breakthrough' status for hepatitis C regimen

    In March Pfizer dropped HCV candidate filibuvir after a strategic review of its pipeline, while last year BMS abandoned its polymerase inhibitor BMS-986094 candidate after a patient death in trials.

  • BMS and Vertex partner on oral hepatitis treatment BMS and Vertex partner on oral hepatitis treatment

    However, the company received a major blow last year when safety issues meant it had to pull a phase II trial investigating daclatasvir in combination with BMS-986094 – an NS5B inhibitor ... VX-135 is a uridine nucleotide analogue that, like BMS-986094,

  • BMS names Francis Cuss as new R&D chief BMS names Francis Cuss as new R&D chief

    of both the leadership and strategy that have been the hallmarks of our success," commented BMS' CEO Lamberto Andreotti. ... This is despite a recent setback when a trial involving nucleotide polymerase (NS5b) inhibitor BMS-986094 was halted on safety

  • Pfizer drops hepatitis C candidate filibuvir Pfizer drops hepatitis C candidate filibuvir

    Bristol-Myers Squibb's nucleotide NS5B polymerase inhibitor BMS-986094 suffered a setback last year, however, after a safety issue merged in a phase II trial looking at its use alongside

  • BMS Q4 results see earnings increase despite fall in sales BMS Q4 results see earnings increase despite fall in sales

    The Onglyza (saxagliptin) diabetes franchise also did well - rising 29 per cent to $198m in the quarter - although BMS noted that the DPP-4 inhibitor sector is becoming increasingly crowded. ... drug BMS-986094 during clinical trials, according to a Wall

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2014 Pharma deals during June 2014

    The acquisitions are not without risk as BMS found when, seven months after paying $2.5bn, it had to discontinue development of Inhibitex product INX-189 in phase II because of ... Inhibitex/ BMS. INX-189 / BMS 986094. Phase II. Jan 2012. Acquisition, 163

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics